Company profile
INFLARX N.V.
NASDAQ:IFRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VILOBELIMAB | phase3 | — | 10 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01319903 | phase1 | completed | 2011-03-01 | 2011-10-01 | InflaRx GmbH | Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 |
| NCT03487276 | phase2 | completed | 2018-02-26 | 2019-05-27 | InflaRx GmbH | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT06555328 | phase2 | terminated | 2025-01-02 | 2026-01-22 | InflaRx GmbH | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa |
| NCT03971643 | phase2 | completed | 2019-05-16 | 2022-01-03 | InflaRx GmbH | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum |
| NCT04812535 | phase2 | terminated | 2021-03-31 | 2024-06-04 | InflaRx GmbH | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. |
FDA applications (0)
No records yet.